United States - English - NLM (National Library of Medicine)

obagi medical products, inc., a division of valeant pharmaceuticals north america llc. - homosalate (unii: v06sv4m95s) (homosalate - unii:v06sv4m95s), octinoxate (unii: 4y5p7mud51) (octinoxate - unii:4y5p7mud51), octocrylene (unii: 5a68wgf6wm) (octocrylene - unii:5a68wgf6wm), zinc oxide (unii: soi2loh54z) (zinc oxide - unii:soi2loh54z) - homosalate 120 mg in 1 g

United States - English - NLM (National Library of Medicine)

wyeth pharmaceuticals llc, a subsidiary of pfizer inc. - coral snake (micrurus fulvius) immune globulin antivenin (equine) (unii: y605xbm2gl) (coral snake (micrurus fulvius) immune globulin antivenin (equine) - unii:y605xbm2gl) - coral snake (micrurus fulvius) immune globulin antivenin (equine) 250 [arb'u] in 10 ml - north american coral snake antivenin (equine) is indicated only for the treatment of envenomation caused by bites of north american coral snakes - micrurus (including the eastern and texas varieties). risk summary there are no available human data that establish developmental toxicity related to the use of north american coral snake antivenin (equine). there are no available animal data informing the north american coral snake antivenin (equine)-associated risk. north american coral snake antivenin (equine) should be given to a pregnant woman only if clearly required. in the us general population, the background risk of major birth defects is 2–4% and of miscarriage is 15–20% in clinically recognized pregnancies. risk summary lactation studies have not been conducted with north american coral snake antivenin (equine). it is not known whether north american coral snake antivenin (equine) is excreted in human milk. north american coral snake antivenin (equine) should be administered to lactating women only if

United States - English - NLM (National Library of Medicine)

valeant pharmaceuticals north america llc - homosalate (unii: v06sv4m95s) (homosalate - unii:v06sv4m95s), meradimate (unii: j9qgd60ouz) (meradimate - unii:j9qgd60ouz), octinoxate (unii: 4y5p7mud51) (octinoxate - unii:4y5p7mud51), octocrylene (unii: 5a68wgf6wm) (octocrylene - unii:5a68wgf6wm), zinc oxide (unii: soi2loh54z) (zinc oxide - unii:soi2loh54z) - homosalate 100 mg in 1 ml

United States - English - NLM (National Library of Medicine)

valeant pharmaceuticals north america llc - titanium dioxide (unii: 15fix9v2jp) (titanium dioxide - unii:15fix9v2jp), zinc oxide (unii: soi2loh54z) (zinc oxide - unii:soi2loh54z) - titanium dioxide 36.7 mg in 1 g

United States - English - NLM (National Library of Medicine)

valeant pharmaceuticals north america llc - titanium dioxide (unii: 15fix9v2jp) (titanium dioxide - unii:15fix9v2jp), zinc oxide (unii: soi2loh54z) (zinc oxide - unii:soi2loh54z) - titanium dioxide 0.80 g in 13.32 g

United States - English - NLM (National Library of Medicine)

valeant pharmaceuticals north america llc - titanium dioxide (unii: 15fix9v2jp) (titanium dioxide - unii:15fix9v2jp), zinc oxide (unii: soi2loh54z) (zinc oxide - unii:soi2loh54z) - titanium dioxide 4.165 g in 85 g

United States - English - NLM (National Library of Medicine)

valeant pharmaceuticals north america llc - titanium dioxide (unii: 15fix9v2jp) (titanium dioxide - unii:15fix9v2jp), zinc oxide (unii: soi2loh54z) (zinc oxide - unii:soi2loh54z) - titanium dioxide 37 mg in 1 g

United States - English - NLM (National Library of Medicine)

valeant pharmaceuticals north america llc - titanium dioxide (unii: 15fix9v2jp) (titanium dioxide - unii:15fix9v2jp), zinc oxide (unii: soi2loh54z) (zinc oxide - unii:soi2loh54z) - titanium dioxide 2.744 g in 56 g

United States - English - NLM (National Library of Medicine)

merz north america, inc. - botulinum toxin type a (unii: e211kpy694) (botulinum toxin type a - unii:e211kpy694) - botulinum toxin type a 50 [usp'u] - xeomin is indicated for the treatment of chronic sialorrhea in patients 2 years of age and older. upper limb spasticity in adult patients xeomin is indicated for the treatment of upper limb spasticity in adult patients. upper limb spasticity in pediatric patients, excluding spasticity caused by cerebral palsy xeomin is indicated for the treatment of upper limb spasticity in pediatric patients 2 to 17 years of age, excluding spasticity caused by cerebral palsy. xeomin is indicated for the treatment of cervical dystonia in adult patients. xeomin is indicated for the treatment of blepharospasm in adult patients. xeomin is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients. xeomin is contraindicated in patients with: - known hypersensitivity to any botulinum toxin product or to any of the components in the formulation [see warnings and precautions (5.3) and description (11)] . - infection at t

United States - English - NLM (National Library of Medicine)

pharmaceutica north america, inc. - gabapentin (unii: 6cw7f3g59x) (gabapentin - unii:6cw7f3g59x) - gabapentin 300 mg